Works by Fagery, Mussab
Results: 5
Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review.
- Published in:
- PharmacoEconomics, 2023, v. 41, n. 10, p. 1229, doi. 10.1007/s40273-023-01292-5
- By:
- Publication type:
- Article
Pharmacogenetic‐guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC‐PGx): A multicenter clinical trial.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 12, p. 1, doi. 10.1111/cts.70083
- By:
- Publication type:
- Article
Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 12, p. 2700, doi. 10.1111/cts.13664
- By:
- Publication type:
- Article
Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing: System Dynamics Modelling for Integrating MCED Tests with Standard Screening: M. Fagery et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 147, doi. 10.1007/s41669-024-00533-3
- By:
- Publication type:
- Article